Skip to main content

RenovoRx, Inc. (RNXT)

NASDAQ: RNXT · Delayed Price · USD
7.50 0.15 (2.04%)
Sep 21, 2021 4:00 PM EDT - Market closed
Market Cap57.20M
Revenue (ttm)n/a
Net Income (ttm)-3.90M
Shares Out7.63M
EPS (ttm)-0.51
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close7.35
Day's Range7.02 - 7.70
52-Week Range6.66 - 16.74
Price Targetn/a
Est. Earnings Daten/a

About RNXT

RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for our lead product candidate RenovoGem. Our therapy platform, RenovoTAMP, combines our patented FDA cleared delivery system, RenovoCath®, with small molecule chemotherapeutic agents that can be forced across the vessel wall using pressure, targeting these anti-cancer drugs locally to the solid tumors. While we anticipate investigating other chemotherapeutic agents for int...

IPO DateAug 26, 2021
CEOShaun Bagai
Stock ExchangeNASDAQ
Ticker SymbolRNXT
Full Company Profile

Financial Performance

Financial Statements


RNXT Stock: The FDA News That Has Biotech Company RenovoRx Rocketing Higher Today

RenovoRx (RNXT) stock is running higher on Tuesday following news that the U.S. Food and Drug Administration granted it new 501(k) clearance. The post RNXT Stock: The FDA News That Has Biotech Company R...

2 weeks ago - InvestorPlace

See Why RenovoRx Stock Is Shooting Higher On Tuesday

The FDA has granted a new 510(k) clearance to RenovoRx Inc's (NASDAQ:RNXT) RenovoCath Delivery System.  The RenovoCath Delivery System is the device component of the Company's initial product, RenovoGem.

2 weeks ago - Benzinga

RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid T...

LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ --  RenovoRx , Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clear...

2 weeks ago - PRNewsWire

RenovoRx Announces Pricing of Initial Public Offering

RenovoRx, Inc., a biopharmaceutical company and innovator in targeted cancer therapy, today announced the pricing of its underwritten initial...

3 weeks ago - PRNewswire

RenovoRx IPO Registration Document (S-1)

RenovoRx, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC